scholarly journals Race disparity in blood sphingolipidomics associated with lupus cardiovascular comorbidity

PLoS ONE ◽  
2019 ◽  
Vol 14 (11) ◽  
pp. e0224496 ◽  
Author(s):  
Samar M. Hammad ◽  
Jasmyn R. Hardin ◽  
Dulaney A. Wilson ◽  
Waleed O. Twal ◽  
Paul J. Nietert ◽  
...  
Keyword(s):  
Cardiovascular Comorbidity ◽  
Race Disparity

scholarly journals Is the use of two versus one long-acting bronchodilator by patients with COPD associated with a higher risk of acute coronary syndrome in real-world clinical practice?

2021 ◽  
Vol 8 (1) ◽  
pp. e000840
Author(s):  
Lianne Parkin ◽  
Sheila Williams ◽  
David Barson ◽  
Katrina Sharples ◽  
Simon Horsburgh ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Clinical Practice ◽  
Real World ◽  
Chronic Obstructive ◽  
Treatment Intensification ◽  
Cardiovascular Comorbidity ◽  
Coronary Syndrome ◽  
Long Acting ◽  
The Impact

BackgroundCardiovascular comorbidity is common among patients with chronic obstructive pulmonary disease (COPD) and there is concern that long-acting bronchodilators (long-acting muscarinic antagonists (LAMAs) and long-acting beta2 agonists (LABAs)) may further increase the risk of acute coronary events. Information about the impact of treatment intensification on acute coronary syndrome (ACS) risk in real-world settings is limited. We undertook a nationwide nested case–control study to estimate the risk of ACS in users of both a LAMA and a LABA relative to users of a LAMA.MethodsWe used routinely collected national health and pharmaceutical dispensing data to establish a cohort of patients aged >45 years who initiated long-acting bronchodilator therapy for COPD between 1 February 2006 and 30 December 2013. Fatal and non-fatal ACS events during follow-up were identified using hospital discharge and mortality records. For each case we used risk set sampling to randomly select up to 10 controls, matched by date of birth, sex, date of cohort entry (first LAMA and/or LABA dispensing), and COPD severity.ResultsFrom the cohort (n=83 417), we identified 5399 ACS cases during 281 292 person-years of follow-up. Compared with current use of LAMA therapy, current use of LAMA and LABA dual therapy was associated with a higher risk of ACS (OR 1.28 (95% CI 1.13 to 1.44)). The OR in an analysis restricted to fatal cases was 1.46 (95% CI 1.12 to 1.91).ConclusionIn real-world clinical practice, use of two versus one long-acting bronchodilator by people with COPD is associated with a higher risk of ACS.

Abstract 201: Generation of Photoactivatable apoA I to Study HDL Transport in vivo Reveals Impaired HDL Recirculation in a Murine Model of Psoriasis

2017 ◽  
Vol 37 (suppl_1) ◽  
Author(s):  
Li-Hao Huang ◽  
Bernd H Zinselmeyer ◽  
Chih-Hao Chang ◽  
Brian T Saunders ◽  
Brian S Kim ◽  
...  
Keyword(s):  
T Cell ◽  
Murine Model ◽  
Structural Changes ◽  
Cardiovascular Outcomes ◽  
Dependent Manner ◽  
Cardiovascular Comorbidity ◽  
Collagen Density

HDL is cardioprotective, but plasma HDL levels do not necessarily predict cardiovascular outcomes. The major HDL-associated protein apoA-I picks up its cholesterol from cells within extravascular compartments to return it to plasma and then bile. Yet, tools are lacking to quantify the important step of HDL transit through extravascular spaces. Here, we developed recombinant photoactivatable apoA-I to quantify endogenous HDL recirculation. Using the tool, we studied HDL passage through skin in healthy mice versus those with experimental psoriasis, wherein collagen density increased in the skin in a CD4 + T cell-dependent manner. In control mice, photoactivated HDL mobilized to plasma within 2 h but was retained in collagen-enriched skin of mice with psoriasis. These data suggest that cardiovascular comorbidity in psoriasis might be linked to T cell-mediated structural changes in skin that impedes systemic recirculation of HDL. This new tool is likely to find wide application in HDL research.

scholarly journals Determination of combination therapy prescribing patterns for the treatment of acute agitation in psychiatric patients: A regression model of patient diagnoses and demographics

2019 ◽  
Vol 9 (5) ◽  
pp. 298-303
Author(s):  
Mark S. Maas ◽  
Karen E. Moeller ◽  
Brittany L. Melton
Keyword(s):  
Combination Therapy ◽  
Regression Model ◽  
Psychiatric Patients ◽  
A Priori ◽  
Young Male ◽  
Binary Logistic Regression ◽  
Prescribing Patterns ◽  
Cardiovascular Comorbidity ◽  
Logistic Regression Models ◽  
Acute Agitation

Abstract Introduction Guidelines for the treatment of acute agitation typically recommend monotherapy with an antipsychotic or a benzodiazepine, but combination therapy is frequently used in practice. We created a regression model to identify which factors lead to the prescribing of combination therapy for acute agitation on a psychiatry unit. Methods We collected retrospective data from hospitalized patients in the psychiatry unit. An a priori alpha of 0.05 was used for binary logistic regression models to determine if and how the number of prescribed medications for acute agitation was influenced by: age, sex, race, cardiovascular comorbidities, and psychiatric diagnoses. Results We identified 1998 encounters from 1200 patients. Patients are significantly more likely to be prescribed combination therapy if they are young, male, and of non-white race or have a diagnosis of central nervous system stimulant use, hallucinogen use, depression, bipolar, cluster B personality, or psychosis. Patients are significantly more likely to be prescribed monotherapy if they have cardiovascular comorbidity or have neurocognitive disorder. Discussion Several demographic or diagnostic factors predict combination therapy prescribing. Acute agitation guidelines should be reviewed to include more clear instructions on combination therapy use.

scholarly journals Features of in-hospital clinical course of pulmonary embolism in patients of different age groups

2020 ◽  
Vol 19 (5) ◽  
pp. 2423
Author(s):  
E. A. Shmidt ◽  
S. A. Berns ◽  
A. G. Neeshpapa ◽  
P. A. Talyzin ◽  
I. I. Zhidkova ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
High Risk ◽  
Clinical Course ◽  
Diastolic Pressure ◽  
Age Groups ◽  
Statistical Processing ◽  
Severity Index ◽  
Cardiovascular Comorbidity ◽  
Vein Thrombosis ◽  
Comorbidity Status

Aim. To study the clinical course and management of patients with pulmonary embolism (PE) of various age groups hospitalized in a cardiology hospital.Material and methods. This prospective single-center study in the period from 2016 to 2018 included 154 patients with PE verified by computed tomography. Statistical processing was conducted using the MedCalcVersion 16.2.1 software package (Softwa, Belgium).Results. In all groups, female patients dominated, but the highest number of women (70,7%) belonged to the group of senile patients, while in the group <60 years, only half of patients with PE were women. Comorbid cardiovascular disease and deep vein thrombosis was diagnosed in eldest patients significantly more often than in those <60 years of age. The highest prevalence of cancer and recurrent PE were identified in the group of elderly patients. Thrombolytic therapy was performed most often in patients 60-75 years old, since these patients had a high risk of 30-day mortality according to Pulmonary Embolism Severity Index, but did not have severe comorbidities, as patients older than 75 years. An increase of right atrium size was found in the group of elderly and senile patients in comparison with patients <60 years. The highest pulmonary artery systolic and diastolic pressure was observed in the patients older than 75 years.Conclusion. In the Kemerovo Oblast, PE most often develops in patients aged 60-75 years and is characterized by a more severe clinical course compared with patients younger than 60 years. Patients over the 60 years of age have severe cardiovascular comorbidity status, atrial fibrillation/flutter and recurrent PE. Surgical treatment for senile patients is limited due to the high risk of postoperative complications, which specifies high mortality. Patients <60 years of age are a third of all patients hospitalized with PE. They have a low risk of mortality, but have an unfavorable course of the hospital period.

scholarly journals The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity

2011 ◽  
Vol 20 (4) ◽  
pp. 303-307 ◽  
Author(s):  
Wolf-Henning Boehncke ◽  
Sandra Boehncke ◽  
Anne-Marie Tobin ◽  
Brian Kirby
Keyword(s):  
Severe Psoriasis ◽  
Cardiovascular Comorbidity

Problems of cardiovascular comorbidity in patients with osteoarthritis

2021 ◽  
Vol 7 (1) ◽  
pp. 9-13
Author(s):  
A. Vol'nyagina ◽  
Elena Belyaeva
Keyword(s):  
Cardiovascular System ◽  
Joint Disease ◽  
Joint Diseases ◽  
Cardiovascular Comorbidity ◽  
Increased Risk ◽  
Comorbid Diseases ◽  
The Impact ◽  
High Comorbidity

Osteoarthritis (OA) is the most common joint disease with high comorbidity. Among comorbid diseases in patients with OA, diseases of the cardiovascular system are in the first place. It is known that comorbid diseases mutually aggravate the course of each of the existing nosologies.It is important to study the impact of concomitant diseases in patients with OA on the quality and duration of life, to analyze the factors that contribute to an increased risk of cardiovascular disasters in patients with degenerative and destructive joint diseases.

Sign in / Sign up

Export Citation Format

Share Document